Inhibiting the type 2 inflammatory pathway with dupilumab is associated with an increase in interleukin-4 and interleukin-18 production.
Jymirah MorrisTolani F OlonisakinJohn A MooreBaDoi PhanDana M ParkerBliss A UribeStephanie J BarelEve M R BowersKathleen M BuchheitTanya M LaidlawStella E LeePublished in: International forum of allergy & rhinology (2022)